Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus ESTERIFIED ESTROGENS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus ESTERIFIED ESTROGENS.
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM vs ESTERIFIED ESTROGENS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of drospirenone (a progestin with antimineralocorticoid and antiandrogenic activity), ethinyl estradiol (an estrogen), and levomefolate calcium (a folate supplement). Prevents ovulation by suppressing gonadotropins; increases cervical mucus viscosity, inhibiting sperm penetration; levomefolate provides folate to reduce neural tube defect risk.
Estrogen replacement therapy; binds to estrogen receptors (ERα and ERβ), activating transcription of estrogen-responsive genes, promoting proliferation of endometrial and breast epithelium, and exerting effects on bone, cardiovascular, and central nervous systems.
One tablet orally once daily for 28 days (21 active tablets containing drospirenone 3 mg, ethinyl estradiol 0.02 mg, and levomefolate calcium 0.451 mg, followed by 7 placebo tablets containing levomefolate calcium 0.451 mg).
1.25 mg orally once daily for 21 days, followed by a 7-day drug-free period per cycle. Adjust based on response.
None Documented
None Documented
Drospirenone: ~30 hours (steady state achieved after 8 days). Ethinyl estradiol: ~13-17 hours (biphasic, terminal). Levomefolate calcium: ~4-6 hours (folate derivatives have longer retention).
Terminal elimination half-life is approximately 10-24 hours, reflecting the prolonged activity of conjugated metabolites and enterohepatic cycling. Steady-state is achieved within 3-5 days.
Drospirenone: ~50% renal (as metabolites), ~40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Levomefolate calcium: ~70% renal (as folate metabolites), ~30% fecal.
Esterified estrogens are metabolized in the liver and undergo enterohepatic recirculation. Approximately 60-80% of the dose is excreted in the urine (as glucuronide and sulfate conjugates), with the remaining 20-40% excreted in feces via bile.
Category D/X
Category C
Progestin + Estrogen
Estrogen